Key features and details
- Produced recombinantly (animal-free) for high batch-to-batch consistency and long term security of supply
- Rabbit monoclonal [EPR10269(B)] to ALAD
- Suitable for: WB
- Reacts with: Mouse, Human
Product nameAnti-ALAD antibody [EPR10269(B)]
See all ALAD primary antibodies
DescriptionRabbit monoclonal [EPR10269(B)] to ALAD
Tested applicationsSuitable for: WBmore details
Unsuitable for: ICC,IHC-P or IP
Species reactivityReacts with: Mouse, Human
Synthetic peptide within Human ALAD aa 250-350. The exact sequence is proprietary.
- Human red blood cell and fetal liver lysates.
Rat: We have preliminary internal testing data to indicate this antibody may not react with this species. Please contact us for more information.
This product is a recombinant monoclonal antibody, which offers several advantages including:
- - High batch-to-batch consistency and reproducibility
- - Improved sensitivity and specificity
- - Long-term security of supply
- - Animal-free production
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
Storage instructionsShipped at 4°C. Store at -20ºC.
Storage bufferPreservative: 0.01% Sodium azide
Constituents: 9% PBS, 40% Glycerol, 0.05% BSA, 50% Tissue culture supernatant
Concentration information loading...
PurityTissue culture supernatant
Our Abpromise guarantee covers the use of ab151697 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|WB||1/1000 - 1/10000. Predicted molecular weight: 36 kDa.|
FunctionCatalyzes an early step in the biosynthesis of tetrapyrroles. Binds two molecules of 5-aminolevulinate per subunit, each at a distinct site, and catalyzes their condensation to form porphobilinogen.
PathwayPorphyrin metabolism; protoporphyrin-IX biosynthesis; coproporphyrinogen-III from 5-aminolevulinate: step 1/4.
Involvement in diseaseDefects in ALAD are the cause of acute hepatic porphyria (AHP) [MIM:612740]. AHP is a form of porphyria. Porphyrias are inherited defects in the biosynthesis of heme, resulting in the accumulation and increased excretion of porphyrins or porphyrin precursors. They are classified as erythropoietic or hepatic, depending on whether the enzyme deficiency occurs in red blood cells or in the liver. AHP is characterized by attacks of gastrointestinal disturbances, abdominal colic, paralysis, and peripheral neuropathy. Most attacks are precipitated by drugs, alcohol, caloric deprivation, infections, or endocrine factors.
Sequence similaritiesBelongs to the ALADH family.
- Information by UniProt
- ALAD antibody
- ALADH antibody
- ALADR antibody
ab151697 has been referenced in 1 publication.
- Chen CP et al. Synergistic antitumor activity of artesunate and HDAC inhibitors through elevating heme synthesis via synergistic upregulation of ALAS1 expression. Acta Pharm Sin B 9:937-951 (2019). PubMed: 31649844